July 30 (Reuters) - Madrigal Pharmaceuticals ( MDGL )
said on Wednesday it has entered a global license agreement for
up to $2 billion with CSPC Pharmaceutical ( CHJTF ) to develop
an oral GLP-1 drug for a type of liver disease.